Janssen R&D Unveils Three New Research Platforms
This article was originally published in The Pink Sheet Daily
With an emphasis on early disease intervention, J&J’s Janssen R&D unit launched three new research platforms – disease prevention, disease interception and the microbiome.
You may also be interested in...
The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.
A pair of technology platforms acquired in the 2010 buyout of Crucell is enabling J&J to produce higher yields of vaccines and deliver safely using adenovirus vectors.
Microbiome-based research is gaining credibility as a means to discover novel therapeutics. Now big pharmas like J&J and Pfizer are evaluating partnering opportunities in the burgeoning field – with potential therapies starting to enter the clinic – as they look to strike the appropriate balance between internal and external research.